Current and planned multicenter trials for patients with primary or metastatic melanoma

Journal of Surgical Oncology

Volumn 104, Issue 4, 2011, Pages 430-437

  Sondak, Vernon K ^a,b   Han, Dale ^a   Deneve, Jeremiah ^a   Kudchadkar, Ragini ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

clinical trials; immunotherapy; melanoma; sentinel node biopsy; surgery

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CANVAXIN; CHIR 265; CISPLATIN; D1/3 MAGE3 HIS PROTEIN; DACARBAZINE; EVEROLIMUS; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GSK 1120212; GSK 2118436; GSK 2132231A; HYBRID PROTEIN; IMATINIB; INTERLEUKIN 2; IPILIMUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN 3; MOLECULAR THERAPY AGENT; NILOTINIB; ONCOVEX; PEGINTERFERON ALPHA2B; PENTETATE TECHNETIUM TC 99M; PV 10; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RO 5185426; TECHNETIUM SULFUR COLLOID TC 99M; TEMOZOLOMIDE; TICILIMUMAB; TORICEL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VELIMOGENE ALIPLASMID; VEMURAFENIB; VINBLASTINE; XL 281;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; COLITIS; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; HEPATITIS; HIGH RISK PATIENT; HUMAN; HYPOPHYSITIS; IMAGE DISPLAY; IMMUNE RESPONSE; LOW DRUG DOSE; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MELANOMA; METASTASIS; MOLECULAR THERAPY; MONOTHERAPY; MORBIDITY; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADICAL LYMPHADENECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; LYMPH NODE EXCISION; MELANOMA; MOLECULAR TARGETED THERAPY; MULTICENTER STUDIES AS TOPIC; RADIOTHERAPY, ADJUVANT; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 80052002462     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21867     Document Type: Review

References (59)

1. Riker AI, Glass F, Perez I, et al.: Cutaneous melanoma: Methods of biopsy and definitive surgical excision. Dermatol Ther 2005; 18: 387-393. (Pubitemid 43096611)
2. Sladden MJ, Balch C, Barzilai DA, et al.: Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev 2009; 4: CD004835.
3. McMasters KM, Noyes RD, Reintgen DS, et al.: Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol 2004; 86: 212-223. (Pubitemid 38880288)
4. Scoggins CR, Bowen AL, Martin RC II, et al.: Prognostic information from sentinel lymph node biopsy in patients with thick melanoma. Arch Surg 2010; 145: 622-627.
5. Scoggins CR, Martin RC, Ross MI, et al.: Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol 2010; 17: 709-717.
6. Morton DL, Thompson JF, Cochran AJ, et al.: Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355: 1307-1317. (Pubitemid 44465459)
7. Faries MB, Thompson JF, Cochran A, et al.: The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: Results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol 2010; 17: 3324-3329.
8. Wallace AM, Hoh CK, Vera DR, et al.: Lymphoseek: A molecular radiopharmaceutical for sentinel node detection. Ann Surg Oncol 2003; 10: 531-538. (Pubitemid 40486916)
9. Wallace AM, Hoh CK, Ellner SJ, et al.: Lymphoseek: A molecular imaging agent for melanoma sentinel lymph node mapping. Ann Surg Oncol 2007; 14: 913-921. (Pubitemid 46175343)
10. Scoggins CR, Ross MI, Reintgen DS, et al.: Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 2006; 24: 2849-2857. (Pubitemid 46630585)
11. Kuo CT, Hoon DS, Takeuchi H, et al.: Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol 2003; 21: 3566-3572. (Pubitemid 46594047)
12. Takeuchi H, Morton DL, Kuo C, et al.: Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 2004; 22: 2671-2680. (Pubitemid 41103755)
13. Mocellin S, Hoon DS, Pilati P, et al.: Sentinel lymph node molecular ultrastaging in patients with melanoma: A systematic review and meta-analysis of prognosis. J Clin Oncol 2007; 25: 1588-1595. (Pubitemid 46733087)
14. Hilari JM, Mangas C, Xi L, et al.: Molecular staging of pathologically negative sentinel lymph nodes from melanoma patients using multimarker, quantitative real-time RT-PCR. Ann Surg Oncol 2009; 16: 177-185.
15. Henderson M, Burmeister B, Thompson J, et al.: Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial. J Clin Oncol 2009; 27: LBA9084.
16. Su LD, Fullen DR, Lowe L, et al.: Desmoplastic and neurotropic melanoma. Cancer 2004; 100: 598-604.
17. Rao NG, Yu HH, Trotti A III, et al.: The role of radiation therapy in the management of cutaneous melanoma. Surg Oncol Clin N Am 2011; 20: 115-131.
18. Kirkwood JM, Sondak VK, Hersey P, et al.: Adjuvant systemic therapy for high-risk melanoma patients. In:, Balch CM, Houghton AN, Sober AJ, Soong S-J, Atkins MB, Thomspson JF, editors. Cutaneous Melanoma, 5th edition. St Louis: Quality Medical Publishing, Inc.: 2009; pp. 669-692.
19. Kirkwood JM, Strawderman MH, Ernstoff MS, et al.: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17. (Pubitemid 26019991)
20. Kirkwood JM, Manola J, Ibrahim J, et al.: A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10: 1670-1677. (Pubitemid 38435557)
21. Eggermont A, Suciu S, Rutkowski P, et al.: Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: Final results of study EORTC 18961. J Clin Oncol 2010; 28: 612s (abs 8505).
22. Kirkwood JM, Ibrahim JG, Sondak VK, et al.: High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18: 2444-2458. (Pubitemid 30415832)
23. Eggermont AM, Suciu S, MacKie R, et al.: Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): Randomised controlled trial. Lancet 2005; 366: 1189-1196. (Pubitemid 41393597)
24. Hancock BW, Wheatley K, Harris S, et al.: Adjuvant interferon in high-risk melanoma: The AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004; 22: 53-61. (Pubitemid 41095114)
25. Pectasides D, Dafni U, Bafaloukos D, et al.: Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol 2009; 27: 939-944.
26. Hauschild A, Weichenthal M, Rass K, et al.: Efficacy of low-dose interferon α 2a 18 versus 60 months of treatment in patients with primary melanoma of ≥ 1.5mm tumor thickness: Results of a randomized phase III DeCOG trial. J Clin Oncol 2010; 28: 841-846.
27. Sondak VK, Gonzalez RJ, Kudchadkar R:, Adjuvant therapy for melanoma: A surgical perspective. Surg Oncol Clin N Am 2011; 20: 105-114.
28. Daud AI, Xu C, Hwu WJ, et al.: Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol published online May 28, 2010.
29. Eggermont AM, Suciu S, Santinami M, et al.: Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372: 117-126. (Pubitemid 351952257)
30. Gogas HJ, Kirkwood JM, Sondak VK:, Chemotherapy for metastatic melanoma: Time for a change ? Cancer 2007; 109: 455-464. (Pubitemid 46190953)
31. Lewis KD, Robinson WA, McCarter M, et al.: Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol 2006; 24: 3157-3163. (Pubitemid 46638954)
32. Koyanagi K, O'Day SJ, Boasberg P, et al.: Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res 2010; 16: 2402-2408.
33. Egen J, Kuhns M, Allison J:, CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nature Immunol 2002; 3: 611-618. (Pubitemid 34752469)
34. Sarnaik AA, Weber JS:, Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J 2009; 15: 169-173.
35. Hodi FS, O'Day SJ, McDermott DF, et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
36. Phan GQ, Weber JS, Sondak VK:, CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: Surgical issues. Ann Surg Oncol 2008; 15: 3014-3021.
37. Lawson D, Lee S, Tarhini A, et al.: E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma. J Clin Oncol 2010; 28: 612s (abs 8504).
38. Sondak VK, Sabel MS, Mule JJ:, Allogeneic and autologous melanoma vaccines: Where have we been and where are we going ? Clin Cancer Res 2006; 12: 2337s-2341s.
39. Hsueh EC, Essner R, Foshag LJ, et al.: Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002; 20: 4549-4554. (Pubitemid 35402957)
40. Morton D, Mozzillo N, Thompson J, et al.: An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol 2007; 25: 474s (abs 8508).
41. Wong SL, Coit DG:, Role of surgery in patients with stage IV melanoma. Curr Opin Oncol 2004; 16: 155-160. (Pubitemid 38402530)
42. Ollila DW, Caudle AS:, Surgical management of distant metastases. Surg Oncol Clin N Am 2006; 15: 385-398.
43. McLoughlin JM, Zager JS, Sondak VK:, Cytoreductive surgery for melanoma. Surg Oncol Clin N Am 2007; 16: 683-693. (Pubitemid 46990944)
44. Sosman JA, Moon J, Tuthill RJ, et al.: A phase II trial of complete resection for stage IV melanoma: Results of Southwest Oncology Group (SWOG) clinical trial S9430. Cancer 2011; March 31 Epub.
45. Lloyd OC:, Regression of malignant melanoma as a manifestation of a cellular immunity response. Proc R Soc Med 1969; 62: 543-545.
46. Restifo NP, Marincola FM, Kawakami Y, et al.: Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996; 88: 100-108.
47. Bedikian AY, Richards J, Kharkevitch D, et al.: A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 2010; 20: 218-226.
48. Thompson JF, Hersey P, Wachter E:, Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res 2008; 18: 405-411.
49. Toda M, Martuza RL, Rabkin SD:, Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol Ther 2000; 2: 324-329.
50. Senzer NN, Kaufman HL, Amatruda T, et al.: Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27: 5763-5771.
51. Sivendran S, Pan M, Kaufman HL, et al.: Herpes simplex virus oncolytic vaccine therapy in melanoma. Expert Opin Biol Ther 2010; 10: 1145-1153.
52. Rosenberg SA, Yang JC, Restifo NP:, Cancer immunotherapy: Moving beyond current vaccines. Nat Med 2004; 10: 909-915. (Pubitemid 39273730)
53. Atkins MB:, Chemotherapy and biochemotherapy. In:, Balch CM, editor. Cutaneous Melanoma. St. Louis: Quality Medical Publishing, Inc.: 2003; pp. 589-601.
54. Flaherty KT, Puzanov I, Kim KB, et al.: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819.
55. Smalley KS, Sondak VK, Weber JS:, c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol 2009; 24: 643-650.
56. Curtin JA, Busam K, Pinkel D, et al.: Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-4346. (Pubitemid 46630793)
57. Kim KB, Eton O, Davis DW, et al.: Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008; 99: 734-740.
58. Perez DG, Suman VJ, Fitch TR, et al.: Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: A North Central Cancer Treatment Group study, N047A. Cancer 2009; 115: 119-127.
59. Hainsworth JD, Infante JR, Spigel DR, et al.: Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: A phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer 2010; 116: 4122-4129.